Meningitis - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 42

Meningitis - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Meningitis Pipeline Review, Q4 2010”, provides an overview of the Meningitis therapeutic pipeline. This report provides information on the therapeutic development for Meningitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningitis. “Meningitis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Meningitis.
- A review of the Meningitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Meningitis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Meningitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Meningitis pipeline depth and focus of Meningitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meningitis Overview
Therapeutics Development
An Overview of Pipeline Products for Meningitis
Meningitis Therapeutics under Development by Companies
Meningitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Meningitis Therapeutics Development
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
InterMune, Inc.
Pfizer Inc.
Eurocine Vaccines AB
Universities/Institutes Involved in Meningitis Therapeutics Development
Meningitis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
4CMenB Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMRV + Menactra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nimenrix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RotaTeq + NeisVac-C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V501 + Menactra + Adacel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Meningitis - Featured News
Sep 12, 2010: Novartis Phase III Study Shows Meningococcal B Vaccine Candidate Could Be First To Provide Broad Coverage Against Deadly Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Global Meningitis Diagnostics Market: Growth Opportuinites and Business Expansion Strategies
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Ebola Viral Infections – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Psychosis – Pipeline Review, H1 2013